Somewhat Positive Press Coverage Somewhat Unlikely to Affect Conatus Pharmaceuticals (CNAT) Share Price

News stories about Conatus Pharmaceuticals (NASDAQ:CNAT) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Conatus Pharmaceuticals earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 46.5859295411467 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Shares of Conatus Pharmaceuticals (NASDAQ CNAT) opened at $4.09 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.69 and a current ratio of 2.69. Conatus Pharmaceuticals has a 1-year low of $1.88 and a 1-year high of $9.40.

Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.13) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.08). The business had revenue of $9.57 million for the quarter, compared to analyst estimates of $16.06 million. Conatus Pharmaceuticals had a negative return on equity of 83.02% and a negative net margin of 80.98%. During the same period in the previous year, the company earned ($0.31) earnings per share. analysts anticipate that Conatus Pharmaceuticals will post -0.65 earnings per share for the current fiscal year.

Several brokerages recently issued reports on CNAT. Seaport Global Securities reiterated a “buy” rating and set a $16.00 price objective on shares of Conatus Pharmaceuticals in a report on Friday, October 6th. Zacks Investment Research upgraded Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 3rd. Finally, HC Wainwright reiterated a “buy” rating and set a $17.00 price objective (down from $18.00) on shares of Conatus Pharmaceuticals in a report on Thursday, November 2nd. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Conatus Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $16.00.

COPYRIGHT VIOLATION WARNING: This story was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Insider Buying and Selling by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)

What are top analysts saying about Conatus Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Conatus Pharmaceuticals and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit